Sandoz, the global leader in generic and biosimilar medicines, announced that the European Commission has granted marketing authorization for Wyost®1 and Jubbonti®2, the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe.
